Ticagrelor has demonstrated higher clinical benefits, including a reduction in death, MI, or stroke, however, it is associated with about 9-19% higher risk of premature discontinuation. Non-adherence to the regimen may increase mortality and morbidity in ACS patients.
1 This infographic highlights a case report for premature ticagrelor discontinuation, and strategies to avoid ticagrelor non-adherence.